Verapamil hydrochloride tablet extended release contraindications: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 8: | Line 8: | ||
1-Severe [[left ventricular dysfunction]] (see [[Verapamil hydrochloride tablet extended release warnings |WARNINGS]])<br> | 1-Severe [[left ventricular dysfunction]] (see [[Verapamil hydrochloride tablet extended release warnings |WARNINGS]])<br> | ||
2-[[Hypotension ]](systolic pressure less than 90 mm Hg) or [[cardiogenic shock]]<br>3-[[Sick sinus syndrome]] (except in patients with a functioning artificial ventricular pacemaker)<br> | 2-[[Hypotension ]](systolic pressure less than 90 mm Hg) or [[cardiogenic shock]]<br>3-[[Sick sinus syndrome]] (except in patients with a functioning artificial ventricular pacemaker)<br> | ||
4-[[Second-|Second-degree AV block]]or [[third-degree AV block]] (except in patients with a functioning artificial ventricular pacemaker)<bR>5-Patients with [[atrial flutter]] or [[atrial fibrillation ]]and an accessory bypass tract (eg, [[Wolff-Parkinson-White]], [[Lown-Ganong-Levine syndromes]]) (see [[Verapamil hydrochloride tablet extended release warnings |WARNINGS]])<br>6-Patients with known [[hypersensitivity ]]to verapamil hydrochloride<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = CALAN SR (VERAPAMIL HYDROCHLORIDE) TABLET, FILM COATED, EXTENDED RELEASE [G.D. SEARLE LLC DIVISION OF PFIZER INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=acb6e57b-af44-432f-a4de-a293a2e20121#nlm34090-1 | publisher = | date = | accessdate = }}</ref> | 4-[[Second-|Second-degree AV block]]or [[third-degree AV block]] (except in patients with a functioning artificial ventricular pacemaker)<bR>5-Patients with [[atrial flutter]] or [[atrial fibrillation ]]and an accessory bypass tract (eg, [[Wolff-Parkinson-White]], [[Lown-Ganong-Levine syndromes]]) (see [[Verapamil hydrochloride tablet extended release warnings |WARNINGS]])<br>6-Patients with known [[hypersensitivity ]]to verapamil hydrochloride<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = CALAN SR (VERAPAMIL HYDROCHLORIDE) TABLET, FILM COATED, EXTENDED RELEASE [G.D. SEARLE LLC DIVISION OF PFIZER INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=acb6e57b-af44-432f-a4de-a293a2e20121#nlm34090-1 | publisher = | date = | accessdate = }}</ref> | ||
Revision as of 20:17, 4 March 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
CONTRAINDICATIONS
Verapamil HCl caplets are contraindicated in:
1-Severe left ventricular dysfunction (see WARNINGS)
2-Hypotension (systolic pressure less than 90 mm Hg) or cardiogenic shock
3-Sick sinus syndrome (except in patients with a functioning artificial ventricular pacemaker)
4-Second-degree AV blockor third-degree AV block (except in patients with a functioning artificial ventricular pacemaker)
5-Patients with atrial flutter or atrial fibrillation and an accessory bypass tract (eg, Wolff-Parkinson-White, Lown-Ganong-Levine syndromes) (see WARNINGS)
6-Patients with known hypersensitivity to verapamil hydrochloride[1]